2023 Fiscal Year Final Research Report
Standardisation of sequential immunotherapy combined with sequential immunotherapy and oligofractionated radiotherapy for recurrence of a small number of abdominal lymph nodes in colorectal cancer.
Project/Area Number |
20K16741
|
Research Category |
Grant-in-Aid for Early-Career Scientists
|
Allocation Type | Multi-year Fund |
Review Section |
Basic Section 52040:Radiological sciences-related
|
Research Institution | Aichi Medical University |
Principal Investigator |
Ito Makoto 愛知医科大学, 医学部, 講師 (40717899)
|
Project Period (FY) |
2020-04-01 – 2024-03-31
|
Keywords | がん / 免疫療法 / 放射線治療 / 寡分割照射 / がん免疫療法 |
Outline of Final Research Achievements |
We aimed to explore the incidence of abscopal effect (AE) when administering radiotherapy to patients with oligoprogressive solid tumours while they are undergoing treatment with immune checkpoint inhibitors (ICIs). In this prospective observational study, oligoprogressive disease was defined as a <20% increase in lesions compared to >2 months before enrolment. We enrolled patients who requested radiotherapy during the ICI rest period. Twelve patients were included in this study. AEs were observed in six (50%) patients. Patients in the AE group had a significantly better 1-year progression-free survival (PFS) rate than those in the non-AE group (p = 0.008). Two patients from the AE group were untreated and progression-free at the last follow-up. No grade 3 or higher toxicities were observed. Patients with oligoprogressive disease may be promising targets with potential for AEs. AEs can lead to improved PFS and, in rare cases, to a certain progression-free period without treatment.
|
Free Research Field |
放射線治療
|
Academic Significance and Societal Importance of the Research Achievements |
がん免疫療法は一部の症例に対して予後改善に大きく貢献していますが奏効しない場合も多いです。そのため何らかの方法でがん免疫を活性化させるという戦略が、求められてきました。放射線治療によりその活性化が得られる現象をアブスコパル効果といいますが、その発生率は非常に低く、十分に期待されてきませんでした。今回の研究結果でアブスコパル効果が高率に期待できる対象が明らかとなり、新たな治療戦略を検討するうえでの礎となると考えています。
|